NCT04116476

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects With Normal and Impaired Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Tanabe Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function

Conditions

• Mild and Moderate Hepatic Impairment

Interventions

Type	Name	Description
DRUG	MT-7117	Single Dose of MT-7117

Timeline

• Start date: 2019-08-01
• Primary completion: 2021-02-16
• Completion: 2021-02-16
• First posted: 2019-10-04
• Last updated: 2023-05-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study